Results of univariate and multivariate Cox regression analysis of possible risk factors and treatment objectives (only significant results shown)
| Parameter . | Response . | PFS . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Univariate analysis | |||||||||
| ISS stage III | — | — | — | — | 2.379 | 1.182-4.788 | .015 | ||
| Platelets <150 000/μL | 0.310 | 0.105-0.921 | .035 | 1.971 | 1.066-3.644 | .030 | 2.288 | 1.079-4.849 | .031 |
| Hemoglobin <9 g/dL | — | — | 1.946 | 0.941-4.024 | .072 | 2.656 | 1.143-6.168 | .023 | |
| LDH ≥250 U/L | — | — | — | — | 0.521 | 1.127-5.637 | .024 | ||
| Lenalidomide pretreatment | — | — | 2.292 | 1.308-4.016 | .004 | 2.794 | 1.315-5.939 | .008 | |
| Bortezomib and lenalidomide pretreatment | 0.374 | 0.147-0.953 | .039 | 3.151 | 1.783-5.568 | .000 | 2.268 | 1.130-4.554 | .021 |
| >2 previous treatment lines | — | — | 1.978 | 1.153-3.394 | .013 | 3.261 | 1.607-6.620 | .001 | |
| Multivariate analysis* | |||||||||
| Platelets <150 000/μL | 1.930 | 1.036-3.596 | .038 | 2.961 | 1.345-6.520 | .007 | |||
| LDH ≥250 U/L | — | — | — | — | 2.878 | 1.238-6.690 | .014 | ||
| Lenalidomide pretreatment | — | — | 2.393 | 1.361-4.206 | .002 | — | — | ||
| Previous stem cell transplantation | — | — | 1.787 | 1.033-3.092 | .038 | — | — | ||
| >2 previous treatment lines | — | — | — | — | 3.030 | 1.482-6.195 | .002 | ||
| Parameter . | Response . | PFS . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Univariate analysis | |||||||||
| ISS stage III | — | — | — | — | 2.379 | 1.182-4.788 | .015 | ||
| Platelets <150 000/μL | 0.310 | 0.105-0.921 | .035 | 1.971 | 1.066-3.644 | .030 | 2.288 | 1.079-4.849 | .031 |
| Hemoglobin <9 g/dL | — | — | 1.946 | 0.941-4.024 | .072 | 2.656 | 1.143-6.168 | .023 | |
| LDH ≥250 U/L | — | — | — | — | 0.521 | 1.127-5.637 | .024 | ||
| Lenalidomide pretreatment | — | — | 2.292 | 1.308-4.016 | .004 | 2.794 | 1.315-5.939 | .008 | |
| Bortezomib and lenalidomide pretreatment | 0.374 | 0.147-0.953 | .039 | 3.151 | 1.783-5.568 | .000 | 2.268 | 1.130-4.554 | .021 |
| >2 previous treatment lines | — | — | 1.978 | 1.153-3.394 | .013 | 3.261 | 1.607-6.620 | .001 | |
| Multivariate analysis* | |||||||||
| Platelets <150 000/μL | 1.930 | 1.036-3.596 | .038 | 2.961 | 1.345-6.520 | .007 | |||
| LDH ≥250 U/L | — | — | — | — | 2.878 | 1.238-6.690 | .014 | ||
| Lenalidomide pretreatment | — | — | 2.393 | 1.361-4.206 | .002 | — | — | ||
| Previous stem cell transplantation | — | — | 1.787 | 1.033-3.092 | .038 | — | — | ||
| >2 previous treatment lines | — | — | — | — | 3.030 | 1.482-6.195 | .002 | ||
HR, hazard ratio; OR, odds ratio.
Cutoff P < 0.3.